Erdal A, et al. - In this secondary analysis, researchers investigated the safety of buprenorphine transdermal system and factors associated with discontinuation due to adverse events in people with advanced dementia and significant depression from nursing homes. These subjects were randomized to active analgesic treatment (acetaminophen/buprenorphine) or identical placebo for 13 weeks. A significantly higher risk of discontinuation, predominantly attributed to psychiatric and neurological adverse events, was reported in active buprenorphine vs placebo group. During the first week of treatment, a significant drop in daytime activity was observed. The tolerability of buprenorphine was further attenuated by the concomitant use of antidepressants.